692 related articles for article (PubMed ID: 21955459)
1. The role of the kidneys in glucose homeostasis: a new path towards normalizing glycaemia.
DeFronzo RA; Davidson JA; Del Prato S
Diabetes Obes Metab; 2012 Jan; 14(1):5-14. PubMed ID: 21955459
[TBL] [Abstract][Full Text] [Related]
2. Renal glucose reabsorption inhibitors to treat diabetes.
Bailey CJ
Trends Pharmacol Sci; 2011 Feb; 32(2):63-71. PubMed ID: 21211857
[TBL] [Abstract][Full Text] [Related]
3. SGLT2 inhibitors to control glycemia in type 2 diabetes mellitus: a new approach to an old problem.
Jabbour SA
Postgrad Med; 2014 Jan; 126(1):111-7. PubMed ID: 24393758
[TBL] [Abstract][Full Text] [Related]
4. Sodium-glucose cotransporter inhibition: therapeutic potential for the treatment of type 2 diabetes mellitus.
Raskin P
Diabetes Metab Res Rev; 2013 Jul; 29(5):347-56. PubMed ID: 23463735
[TBL] [Abstract][Full Text] [Related]
5. SGLT2 inhibitors: a new emerging therapeutic class in the treatment of type 2 diabetes mellitus.
Ghosh RK; Ghosh SM; Chawla S; Jasdanwala SA
J Clin Pharmacol; 2012 Apr; 52(4):457-63. PubMed ID: 21543663
[TBL] [Abstract][Full Text] [Related]
6. Probing SGLT2 as a therapeutic target for diabetes: basic physiology and consequences.
Gallo LA; Wright EM; Vallon V
Diab Vasc Dis Res; 2015 Mar; 12(2):78-89. PubMed ID: 25616707
[TBL] [Abstract][Full Text] [Related]
7. Ipragliflozin and other sodium-glucose cotransporter-2 (SGLT2) inhibitors in the treatment of type 2 diabetes: preclinical and clinical data.
Kurosaki E; Ogasawara H
Pharmacol Ther; 2013 Jul; 139(1):51-9. PubMed ID: 23563279
[TBL] [Abstract][Full Text] [Related]
8. Sodium glucose co-transporter 2 (SGLT2) inhibitors: novel antidiabetic agents.
Washburn WN
Expert Opin Ther Pat; 2012 May; 22(5):483-94. PubMed ID: 22583331
[TBL] [Abstract][Full Text] [Related]
9. The Role of the Kidney and SGLT2 Inhibitors in Type 2 Diabetes.
Katz PM; Leiter LA
Can J Diabetes; 2015 Dec; 39 Suppl 5():S167-75. PubMed ID: 26654860
[TBL] [Abstract][Full Text] [Related]
10. Targeting renal glucose reabsorption to treat hyperglycaemia: the pleiotropic effects of SGLT2 inhibition.
Vallon V; Thomson SC
Diabetologia; 2017 Feb; 60(2):215-225. PubMed ID: 27878313
[TBL] [Abstract][Full Text] [Related]
11. SGLT2 inhibitors: a promising new therapeutic option for treatment of type 2 diabetes mellitus.
Misra M
J Pharm Pharmacol; 2013 Mar; 65(3):317-27. PubMed ID: 23356840
[TBL] [Abstract][Full Text] [Related]
12. The kidney as a new target for antidiabetic drugs: SGLT2 inhibitors.
Cangoz S; Chang YY; Chempakaseril SJ; Guduru RC; Huynh LM; John JS; John ST; Joseph ME; Judge R; Kimmey R; Kudratov K; Lee PJ; Madhani IC; Shim PJ; Singh S; Singh S; Ruchalski C; Raffa RB
J Clin Pharm Ther; 2013 Oct; 38(5):350-9. PubMed ID: 23909868
[TBL] [Abstract][Full Text] [Related]
13. Development of sotagliflozin, a dual sodium-dependent glucose transporter 1/2 inhibitor.
Lapuerta P; Zambrowicz B; Strumph P; Sands A
Diab Vasc Dis Res; 2015 Mar; 12(2):101-10. PubMed ID: 25690134
[TBL] [Abstract][Full Text] [Related]
14. SGLT2 inhibition: a novel prospective strategy in treatment of diabetes mellitus.
Deshmukh AB; Patel MC; Mishra B
Ren Fail; 2013; 35(4):566-72. PubMed ID: 23438184
[TBL] [Abstract][Full Text] [Related]
15. [Role of the kidneys in glucose homeostasis. Implication of sodium-glucose cotransporter 2 (SGLT2) in diabetes mellitus treatment].
Girard J
Nephrol Ther; 2017 Apr; 13 Suppl 1():S35-S41. PubMed ID: 28577741
[TBL] [Abstract][Full Text] [Related]
16. Beyond Glycosuria: Exploring the intrarenal effects of SGLT₋₂ inhibition in diabetes.
Thomas MC; Jandeleit-Dahm K; Bonnet F
Diabetes Metab; 2014 Dec; 40(6 Suppl 1):S17-22. PubMed ID: 25554067
[TBL] [Abstract][Full Text] [Related]
17. Combined SGLT1 and SGLT2 Inhibitors and Their Role in Diabetes Care.
Danne T; Biester T; Kordonouri O
Diabetes Technol Ther; 2018 Jun; 20(S2):S269-S277. PubMed ID: 29916741
[TBL] [Abstract][Full Text] [Related]
18. Experimental type II diabetes and related models of impaired glucose metabolism differentially regulate glucose transporters at the proximal tubule brush border membrane.
Chichger H; Cleasby ME; Srai SK; Unwin RJ; Debnam ES; Marks J
Exp Physiol; 2016 Jun; 101(6):731-42. PubMed ID: 27164183
[TBL] [Abstract][Full Text] [Related]
19. Energy balance and metabolic changes with sodium-glucose co-transporter 2 inhibition.
Rajeev SP; Cuthbertson DJ; Wilding JP
Diabetes Obes Metab; 2016 Feb; 18(2):125-34. PubMed ID: 26403227
[TBL] [Abstract][Full Text] [Related]
20. The role of the kidneys in glucose homeostasis in type 2 diabetes: clinical implications and therapeutic significance through sodium glucose co-transporter 2 inhibitors.
Wilding JP
Metabolism; 2014 Oct; 63(10):1228-37. PubMed ID: 25104103
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]